OncoMatch/Clinical Trials/NCT04322955
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
Is NCT04322955 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cabozantinib and Nivolumab for kidney cancer.
Treatment: Cabozantinib · Nivolumab — The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Radiographically consistent with metastatic renal cell carcinoma (with subsequent pathologic confirmation of renal cell carcinoma with a clear cell component) OR histological/ cytological evidence of metastatic renal cell carcinoma with a clear cell component
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: PD-1/PD-L1 axis inhibitor
Prior treatment with any therapy on the PD-1/PD-L1 axis or anti- CTLA-4 inhibitors
Cannot have received: CTLA-4 inhibitor
Prior treatment with any therapy on the PD-1/PD-L1 axis or anti- CTLA-4 inhibitors
Cannot have received: any therapy for metastatic renal cell carcinoma
No prior therapy for metastatic renal cell carcinoma
Cannot have received: investigational drug
Treatment with any investigational drug within 28 days prior to registration
Lab requirements
Blood counts
Demonstrate adequate organ function as defined in the protocol; all screening labs to be obtained within 14 days prior to registration.
Kidney function
Demonstrate adequate organ function as defined in the protocol; all screening labs to be obtained within 14 days prior to registration.
Liver function
Demonstrate adequate organ function as defined in the protocol; all screening labs to be obtained within 14 days prior to registration.
Demonstrate adequate organ function as defined in the protocol; all screening labs to be obtained within 14 days prior to registration.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Rutgers Cancer Institute of New Jersey · New Brunswick, New Jersey
- Columbia University Irving Medical Center · New York, New York
- Cleveland Clinic · Cleveland, Ohio
- Ohio State University Wexner Medical Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify